✓ Translated by DotMD AI Clinical Council Source: Journal of consulting and clinical psychology • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #17295580 ↗

Randomized Controlled Trial: Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials

Original Paper Title: “Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Thus, the congruence of patients' treatment preference and the treatment that they ultimately received influenced the development of the therapeutic alliance. Because alliance is a robust predictor of outcome, treatment preferences may need to be carefully considered in randomized controlled trial settings.
  • Study Design & Sample: Randomized Controlled Trial published in Journal of consulting and clinical psychology (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of consulting and clinical psychology (2007), this randomized controlled trial evaluating human clinical outcomes investigated: The influence of treatment preferences on the development of the therapeutic alliance was investigated. Key clinical takeaway: Thus, the congruence of patients' treatment preference and the treatment that they ultimately received influenced the development of the therapeutic alliance. Because alliance is a robust predictor of outcome, treatment preferences may need to be carefully considered in randomized controlled trial settings.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of consulting and clinical psychology, 2007-02-15; Randomized Controlled Trial; Rigor 88/100): Thus, the congruence of patients' treatment preference and the treatment that they ultimately received influenced the development of the therapeutic alliance. Because alliance is a robust predictor of outcome, treatment preferences may need to be carefully considered in randomized controlled trial settings.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: drx-choice-childrens-stuffy-nose-and-chest-congestion-guaifenesin-and → Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Rx: sertraline-hcl → Condition: bladder-stone → Condition: testicular-torsion →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 17295580: Randomized Controlled Trial: Treatment preferences affect the therapeutic alliance: implications for randomized controlled trials

3 of 3 Free Questions Remaining